Vical Provides VL-2397 Updates at BIO International Convention
May 31 2016 - 6:30AM
Vical Incorporated (Nasdaq:VICL) announced today that the company
will present an update on its investigational antifungal product
candidate, VL-2397, at the BIO International Convention (San
Francisco, June 6 - 9).
Andrew Hopkins, Vical’s Director Corporate
Development and Project Management, will present at the Global
Workshop for Novel Anti-Infectives. Vical was selected as one of
ten companies to present during the workshop, which is being
co-hosted by the Innovative Medicines Initiative (IMI), The
Wellcome Trust-funded Community for Open Antimicrobial Drug
Discovery and the IMI funded ENABLE project. Company presentations
will be assessed by an expert panel and the audience, selecting the
best presentation for international promotion following the
workshop. The workshop will take place at the BIO 2016 Convention
on Monday, June 6, 2016 from 11:00am-12:30pm at the Moscone
Convention Center.
About VL-2397VL-2397
exemplifies a new class of antifungal compounds for the treatment
of systemic fungal infections. Systemic fungal infections are
major causes of morbidity and mortality in immunocompromised
patients, such as transplant recipients, in patients undergoing
chemotherapy and in patients in intensive care units. In
preclinical studies to date, VL-2397 has demonstrated faster
antifungal activity than marketed drugs and activity against
azole-resistant fungal pathogens. In March 2016 Vical initiated a
Phase 1 clinical study to evaluate safety, tolerability and
pharmacokinetics of VL-2397 at single and multiple ascending doses
in healthy volunteers at a single U.S. clinical site. VL-2397 was
initially developed by Astellas Pharma Inc. (TOKYO: 4503). In March
2015, Astellas granted Vical an exclusive worldwide license to
develop and commercialize VL-2397.
About VicalVical develops
biopharmaceutical products for the prevention and treatment of
chronic or life-threatening infectious diseases, based on its
patented DNA delivery technologies and other therapeutic
approaches. Additional information on Vical is available at
www.vical.com.
Forward-Looking StatementsThis
press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include
statements about the potential uses and benefits of VL-2397, the
parameters and timing of the Phase 1 trial, the potential market
opportunity for VL-2397 and Vical’s development plans and strategy
with respect to VL-2397. Risks and uncertainties include whether
Vical or others will continue development of VL-2397; whether
planned clinical development of VL-2397 will continue as expected,
or at all; whether the results of clinical studies will be
consistent with prior preclinical studies or will otherwise merit
further development; whether Vical or its collaborative partners
will seek or gain approval to market any product candidates,
including VL-2397 and additional risks set forth in the company's
filings with the Securities and Exchange Commission. These
forward-looking statements represent the company's judgment as of
the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking
statements.
Tony Ramos
(858) 646-1127
Website: www.vical.com
Vical (NASDAQ:VICL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Apr 2023 to Apr 2024